Pacira (PCRX) Rips Over 22% Following Q3 Results, EXPAREL FDA Approval
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharmaceuticals (NASDAQ: PCRX) is ripping higher Monday morning, following strong Q3 results, and a new EXPAREL FDA approval.
The stock is up over 22 percent early.
The stock is up over 22 percent early.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- Merchants & Marine Bancorp posts Q2 earnings surge after acquisition
- SpyGlass Pharma (SGP) Reports Q2 Loss of $0.59
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
